Filing Flows

Filing Flows › Companies › Decoy Therapeutics › Cash flow

Decoy Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$2.7M in Q2 2026 · −$8.3M over twelve months

Operating cash flow−$2.7M
Free cash flow−$2.7M

Analysis

In Q2 2026, Decoy Therapeutics generated −$2.7M of operating cash flow. That is $1.8M less than in Q2 2025 (−$862K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$8.3M; the largest uses were operating cash flow ($8.3M); besides operations, cash came from other financing ($14.7M), other investing ($722K); the cash balance rose by $7.5M.

Operating cash flow was −$2.7M against net income of −$2.4M. The largest differences: payables −$231K, stock-based pay +$206K, accrued liabilities −$29K.

Free cash flow

Decoy Therapeutics: free cash flow by quarterDecoy Therapeutics: free cash flow by quarter−$1.4MQ3 2024−$743KQ4 2024−$1.2MQ1 2025−$862KQ2 2025−$1.6MQ3 2025−$1.1MQ4 2025−$2.9MQ1 2026−$2.7MQ2 2026
Operating cash flow less capital spending.
Decoy Therapeutics: operating cash flow against capital spendingDecoy Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$1.4M$0Q3 2024−$743K$0Q4 2024−$1.2M$0Q1 2025−$862K$0Q2 2025−$1.6M$0Q3 2025−$1.1M$0Q4 2025−$2.9M$0Q1 2026−$2.7M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$2.7M, Capital spending $0.

Capital allocation, year by year

Decoy Therapeutics: where the cash came from (up) and went (down), by fiscal yearDecoy Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsFY2021: Operating cash flow −$10.2MFY2021: Net borrowing −$477KFY2021FY2022: Operating cash flow −$17.6MFY2022FY2023: Operating cash flow −$12.8MFY2023: Net borrowing −$281KFY2023FY2024: Operating cash flow −$4.5MFY2024: Net borrowing −$467KFY2024FY2025: Operating cash flow −$4.8MFY2025: Net borrowing −$222KFY2025: Shares issued $185KFY2025: Capital spending −$577KFY2025: Acquisitions −$8.5M$185KFY2025
Over these 5 years operating cash flow totalled −$50.0M; the largest uses were operating cash flow ($50.0M) and acquisitions ($8.5M). Cash-flow statements as filed.

Where the cash came from and went

Decoy Therapeutics: sources (+) and uses (−) of cash, Q2 2026Decoy Therapeutics: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$2.7MOther financing$2.6MShares issued$552KCash drawn (+) / kept (−)−$468KNot reconciled−$42K
Decoy Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Decoy Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$14.7MOperating cash flow−$8.3MCash drawn (+) / kept (−)−$7.5MOther investing$722KShares issued$380K

From profit to cash

Decoy Therapeutics: net income to operating cash flow, Q2 2026Decoy Therapeutics: net income to operating cash flow, Q2 2026Net income−$2.4MDepreciation & amortization$14KStock-based pay$206KPayables−$231KAccrued liabilities−$29KPrepaid and other assets−$11KOperating cash flow−$2.7M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$2.7M—$552K−$468K−$2.7M
Q1 2026−$2.9M——$2.9M−$2.9M
Q4 2025−$1.1M——−$5.9M−$1.1M
Q3 2025−$1.6M——−$4.0M−$1.6M
Q2 2025−$862K−$112K−$72K$1.0M−$862K
Q1 2025−$1.2M−$110K$429K$636K−$1.2M
Q4 2024−$743K−$107K—$850K−$743K
Q3 2024−$1.4M−$70K—−$11K−$1.4M

Decoy Therapeutics: income statement and cash flow

Decoy Therapeutics, Q2 2026: revenue $228K. The chart follows the revenue to costs, profit and cash.

Decoy Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.